News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

LOINC version 2.81 release

Arabic and Czech translations, more than 4,000 new concepts boost global interoperability in latest LOINC® release

Regenstrief Institute’s latest LOINC® content update on August 12, introduces two new linguistic variants: Arabic, for users in Jordan,

Regenstrief President and CEO Rachel Patzer, PhD, MPH.

Regenstrief CEO among national honorees for ground-breaking achievements in transplantation

SAN FRANCISCO – Regenstrief Institute President and Chief Executive Officer Rachel Patzer, PhD, MPH, is among a select group

LOINC 2025 Conference - Montreal, Canada

Regenstrief to host 2025 LOINC® conference in Montréal, Canada, Oct. 7-10

First LOINC conference in Canada — home to one of LOINC’s largest user bases  Regenstrief Institute Health Data Standards

Katie Ross-Driscoll, PhD

Regenstrief researcher receives Showalter award to improve access to organ transplants using learning health systems approach

Regenstrief Institute Research Scientist Katie Ross-Driscoll, PhD, MPH, has been awarded a 2025 Ralph W. and Grace M. Showalter